GGrantIndex
← Search

PACLITAXEL AND PSC 833 IN METASTATIC COLORECTAL CARCINOMA

$0M01FY2001RRNIH

Stanford University, Stanford CA

Investigators

Linked publications & trials

Abstract

Valspodar (PSC 833) is a new immunosuppresive and new nephrotoxic cyclosporine analog which is a potent inhibitor of P-glycoprotein. Pgp is expressed in a high percentage of colon cancers and may be an important mechanism of resistance to paclitaxel. The goal of this study was to access the remission rate of paclitaxel in PSC in refractory/metastatic colorectal cancer.

View original record on NIH RePORTER →